COMPARISON OF GEMFIBROZIL AND LOVASTATIN IN PATIENTS WITH HIGH LOW-DENSITY-LIPOPROTEIN AND LOW HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS

被引:7
作者
MCKENNEY, JM [1 ]
BARNETT, MD [1 ]
WRIGHT, JT [1 ]
PROCTOR, JP [1 ]
机构
[1] VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, SCH MED, RICHMOND, VA 23298 USA
关键词
D O I
10.1001/archinte.152.9.1781
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The efficacy of gemfibrozil and lovastatin in the treatment of patients who have an elevated low-density lipoprotein cholesterol (LDL-C) level and a low high-density lipoprotein cholesterol (HDL-C) level was compared. Methods.-After at least 6 weeks of a choleserol-lowering diet, 17 patients who had a mean baseline LDL-C level above 4.14 mmol/L (160 mg/dL) and an HDL-C level below 1.03 mmol/L (40 mg/dL) received gemfibrozil 600 mg twice daily and lovastatin 20 mg twice daily each for 6 weeks according to a randomized, crossover, double-blind research design. Results.-Lovastatin and gemfibrozil reduced LDL-C levels 34% and 9% and raised HDL-C levels 15% and 18%, respectively. Conclusions.-Lovastatin is more effective in lowering LDL-C levels and is as effective as gemfibrozil in increasing HDL-C levels in these patients.
引用
收藏
页码:1781 / 1787
页数:7
相关论文
共 54 条
[1]   EFFECT OF A MODIFIED, WELL-TOLERATED NIACIN REGIMEN ON SERUM TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND THE CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN RATIO [J].
ALDERMAN, JD ;
PASTERNAK, RC ;
SACKS, FM ;
SMITH, HS ;
MONRAD, ES ;
GROSSMAN, W .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (12) :725-729
[2]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[3]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[4]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[5]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[6]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255
[7]   SUMMARY ESTIMATES OF CHOLESTEROL USED TO PREDICT CORONARY HEART-DISEASE [J].
CASTELLI, WP ;
ABBOTT, RD ;
MCNAMARA, PM .
CIRCULATION, 1983, 67 (04) :730-734
[8]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838
[9]   THE TRIGLYCERIDE ISSUE - A VIEW FROM FRAMINGHAM [J].
CASTELLI, WP .
AMERICAN HEART JOURNAL, 1986, 112 (02) :432-437
[10]   THE ROLE OF INDIVIDUAL-DIFFERENCES IN LIPOPROTEIN, ARTERY WALL, GENDER, AND BEHAVIORAL-RESPONSES IN THE DEVELOPMENT OF ATHEROSCLEROSIS [J].
CLARKSON, TB ;
KAPLAN, JR ;
ADAMS, MR .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1985, 454 :28-45